WO2010004816A1 - Inhibiteur de la dégranulation des mastocytes - Google Patents

Inhibiteur de la dégranulation des mastocytes Download PDF

Info

Publication number
WO2010004816A1
WO2010004816A1 PCT/JP2009/060220 JP2009060220W WO2010004816A1 WO 2010004816 A1 WO2010004816 A1 WO 2010004816A1 JP 2009060220 W JP2009060220 W JP 2009060220W WO 2010004816 A1 WO2010004816 A1 WO 2010004816A1
Authority
WO
WIPO (PCT)
Prior art keywords
degranulation
microrna
sirna
mast cells
substance
Prior art date
Application number
PCT/JP2009/060220
Other languages
English (en)
Japanese (ja)
Inventor
陽史 山田
哲郎 吉田
Original Assignee
協和発酵キリン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 協和発酵キリン株式会社 filed Critical 協和発酵キリン株式会社
Publication of WO2010004816A1 publication Critical patent/WO2010004816A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne : un inhibiteur de la dégranulation d’un mastocyte qui renferme, en tant que principe actif, une substance capable d’inhiber le processus de biosynthèse de microARN à partir d’un précurseur de microARN, telle qu’une substance capable d’inhiber l’expression du gène Dicer1 ; un procédé d’inhibition de la dégranulation d’un mastocyte ; et un agent thérapeutique pour une maladie induite par l’anomalie dans un mastocyte.
PCT/JP2009/060220 2008-07-07 2009-06-04 Inhibiteur de la dégranulation des mastocytes WO2010004816A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-177109 2008-07-07
JP2008177109A JP2011190176A (ja) 2008-07-07 2008-07-07 肥満細胞の脱顆粒抑制剤

Publications (1)

Publication Number Publication Date
WO2010004816A1 true WO2010004816A1 (fr) 2010-01-14

Family

ID=41506938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/060220 WO2010004816A1 (fr) 2008-07-07 2009-06-04 Inhibiteur de la dégranulation des mastocytes

Country Status (2)

Country Link
JP (1) JP2011190176A (fr)
WO (1) WO2010004816A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006320327A (ja) * 2002-07-26 2006-11-30 Chiron Corp 修飾された低分子干渉ｒｎａ分子および使用方法
JP2007000002A (ja) * 2003-07-16 2007-01-11 Genecare Research Institute Co Ltd アルキル化薬感受性を上昇させる方法
WO2008029790A1 (fr) * 2006-09-04 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Nouvel acide nucléique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006320327A (ja) * 2002-07-26 2006-11-30 Chiron Corp 修飾された低分子干渉ｒｎａ分子および使用方法
JP2007000002A (ja) * 2003-07-16 2007-01-11 Genecare Research Institute Co Ltd アルキル化薬感受性を上昇させる方法
WO2008029790A1 (fr) * 2006-09-04 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Nouvel acide nucléique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABE,T. ET AL.: "Eosinophil chemotactic factor released from murine bone marrow derived cultured mast cells", ARERUGI, vol. 39, no. 2, 1990, pages 69 - 74 *
BILEN,J. ET AL.: "MicroRNA pathways modulate polyglutamine-induced neurodegeneration", MOL CELL, vol. 24, no. 1, 2006, pages 157 - 163 *
CHENDRIMADA,T.P. ET AL.: "TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing", NATURE, vol. 436, no. 7051, 2005, pages 740 - 744 *
KOK,K.H. ET AL.: "Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA", J BIOL CHEM, vol. 282, no. 24, 2007, pages 17649 - 17657 *
KUEHN,H.S. ET AL.: "G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation", IMMUNOL LETT, vol. 113, no. 2, 2007, pages 59 - 69 *
MATSUDA,S. ET AL.: "Molecular cloning and characterization of a novel human gene (HERNA) which encodes a putative RNA-helicase", BIOCHIM BIOPHYS ACTA, vol. 1490, no. 1-2, 2000, pages 163 - 169 *
TEXTOR,B. ET AL.: "JunB is required for IgE- mediated degranulation and cytokine release of mast cells", J IMMUNOL, vol. 179, no. 10, 2007, pages 6873 - 6880 *

Also Published As

Publication number Publication date
JP2011190176A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
EP3277815B1 (fr) Composés d'oligonucléotides pour traiter la pré-éclampsie et d'autres troubles angiogéniques
CA2583375C (fr) Regulation d'oncogenes par des micro-arn
EP3190186B1 (fr) Expression des miarn dans le tissu placentaire
JP6414886B2 (ja) 抗癌治療に用いられる長鎖非コードｒｎａ
WO2009148137A1 (fr) Acide nucléique capable de réguler la dégranulation d'un mastocyte
US20090220589A1 (en) Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
JPWO2009044899A1 (ja) 細胞の増殖を制御する核酸
CN107267625B (zh) lncRNA作为生物标志物在肝癌诊疗中的用途
EP2077326A1 (fr) Nouvel acide nucléique
JP2011519951A (ja) ｍｉＲＮＡによる薬物治療の増強
JPWO2008084319A1 (ja) 新規核酸
WO2011019074A1 (fr) Acide nucléique qui contrôle la fibrose de cellules ou d'organes
US20100292299A1 (en) Nucleotide Motifs Providing Localization Elements and Methods of Use
CN112933112B (zh) 氧化石墨烯或其调控分子在制备促进糖尿病创面修复的药物中的应用
WO2011111715A1 (fr) Acide nucléique apte à réguler le cycle cellulaire
EP2904102B1 (fr) Modulation de l'activité arn et de la perméabilité vasculaire
CN115666590A (zh) 口腔鳞癌相关生物标志物及诊断和治疗方法
WO2010004816A1 (fr) Inhibiteur de la dégranulation des mastocytes
JP2006180710A (ja) Ｋｌｆ５遺伝子の発現を抑制するｒｎａ
WO2011074652A1 (fr) Acide nucléique capable d'inhiber l'expression de hif-2a
WO2011130464A1 (fr) Régulation traductionnelle de sparc par les micro-arn mir29a, b et c
WO2011010737A1 (fr) Acide nucléique guide utilisé dans le clivage de micro-arn
JP5263729B2 (ja) ネコ伝染性腹膜炎ウイルス（ｆｉｐｖ）の予防及び治療剤
JP2021075473A (ja) 中皮腫の予防・治療剤
WO2013113252A1 (fr) Procédé de régulation du niveau d'expression du gène cpy et utilisation de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09794263

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 09794263

Country of ref document: EP

Kind code of ref document: A1